All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

IRX-2 Immunotherapy Misses EFS End Point in Newly Diagnosed Head and Neck Cancer

July 27th 2022

IRX-2 failed to demonstrate a statistically significant improvement in event-free survival as neoadjuvant therapy compared with standard of care in patients with newly diagnosed, stage II, III, or IVA squamous cell carcinoma of the oral cavity.

Direct Partnership With Patients May Accelerate Cancer Research and Precision Oncology

July 27th 2022

During the past several decades, cancer research has produced revolutionary discoveries leading to dramatic results for many patients.

LAG-3 Fills a Complex Role in the Immune System

July 27th 2022

The LAG-3 pathway has emerged as the next target for the use of immune checkpoint inhibitors in oncology.

Niraparib Maintenance Prolongs PFS in Newly Diagnosed Advanced Ovarian Cancer After Response to Chemotherapy

July 26th 2022

Maintenance therapy with niraparib significantly improved progression-free survival compared with placebo in Chinese patients with newly diagnosed advanced ovarian cancer who achieved a complete response or partial response to first-line chemotherapy.

Zilovertamab/Ibrutinib Combo Under Exploration to Fill Unmet Need in Relapsed/Refractory MCL

July 26th 2022

The addition of zilovertamab to ibrutinib will be compared with ibrutinib plus placebo in patients with relapsed/refractory mantle cell lymphoma as part of the phase 3 ZILO-301 trial.

Belantamab Mafodotin/Pembrolizumab Combo Elicits Favorable ORR in Heavily Pretreated Multiple Myeloma

July 26th 2022

The addition of pembrolizumab to belantamab mafodotin resulted in a higher overall response rate in patients with relapsed/refractory multiple myeloma than what has been observed with the antibody-drug conjugate alone, according to results from the phase 1/2 DREAMM-4 trial.

Frontline Enfortumab Vedotin Plus Pembrolizumab Elicits Responses in Advanced Urothelial Cancer

July 26th 2022

Enfortumab vedotin-ejfv plus pembrolizumab induced encouraging responses when used in the frontline treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are not eligible to receive cisplatin-based chemotherapy.

Weaver Elected to Prestigious National Academy of Sciences

July 26th 2022

Casey Weaver, MD, the Wyatt and Susan Haskell Endowed Chair for Medical Excellence in the Department of Pathology, was elected to the prestigious and esteemed National Academy of Sciences.

Dr. Sznol on the Significance of the Relatlimab/Nivolumab Approval in Metastatic Melanoma

July 26th 2022

Mario Sznol, MD, explains the evaluation of efficacy and safety when examining the benefits of new immunotherapy combinations in cancer.

New Approvals Help Fill Unmet Need in Treating Chronic GVHD

July 26th 2022

A panel of hematology experts discuss use of steroids in the first-line setting as well as several subsequent-line treatments that have recently received FDA approval for patients with steroid-refractory chronic GVHD, which affects up to 50% of patients.

Bomedemstat Demonstrates Early Promise in Advanced Myelofibrosis

July 26th 2022

Single-agent bomedemstat was found to improve symptom scores, bone marrow fibrosis, spleen volumes, and anemia in patients with advanced myelofibrosis, according to findings from the phase 1/2 IMG-7289-CTP-102 trial (NCT03136185) presented during the 2022 EHA Congress.

Selinexor/Ruxolitinib Combo Shows Early Activity, Tolerability in Treatment-Naïve Myelofibrosis

July 25th 2022

A combination comprised of selinexor (Xpovio) and ruxolitinib (Jakafi) induced rapid spleen responses at week 12 and showcased a manageable toxicity profile in patients with treatment-naïve myelofibrosis.

Diversify Your Cancer Clinical Trials With New Recruitment and Retention Resources

July 25th 2022

The American Society of Clinical Oncology and the Association of Community Cancer Centers today jointly released two resources to help research sites increase the racial and ethnic equity, diversity, and inclusion in cancer clinical trials.

Immunotherapy May Represent an Exciting Development in Angiosarcoma Treatment

July 25th 2022

Although systemic treatments are utilized for angiosarcoma, an aggressive and rare subset of a rare cancer, the efficacy achieved with these options is not as good as it needs to be. Immunotherapy may be able to address the unmet need for a systemic treatment in this disease.

CHMP Recommends Restricting Third-Line Rucaparib Use in BRCA+ Ovarian Cancer

July 25th 2022

The European Medicines Agency Committee for Medicinal Products for Human Use has recommended that rucaparib no longer be used as monotherapy for the third-line treatment of patients with platinum-sensitive, relapsed or progressive BRCA-mutated high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Pembrolizumab Post-Nephrectomy Extends Distant Metastasis-Free Survival, PFS2 in RCC

July 25th 2022

Toni K. Choueiri, MD, explains significant findings from the long-term efficacy analysis of the KEYNOTE-564 study and highlights the significance of these data for the field of RCC.

Teclistamab Approaches EU Approval for Relapsed/Refractory Multiple Myeloma

July 25th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the conditional marketing authorization of teclistamab for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and whose cancer has worsened since receiving the last treatment.

FDA Grants Priority Review to Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer

July 25th 2022

The FDA has accepted and granted priority review to a supplemental biologics license application for the use of trastuzumab deruxtecan in the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received 1 prior therapy in the metastatic setting.

New Gene Profiling Technology Reveals Melanoma Biomarkers

July 25th 2022

UC Davis cancer researchers hope new technology will help diagnose and treat melanoma more successfully.

Immune Checkpoint Inhibitors at ASCO: Long-term Efficacy Data Mount

July 25th 2022

Twelve years after key research into immune checkpoint inhibitor therapy first made a splash at the American Society of Clinical Oncology Annual Meeting, evidence continues to mount that supports the durability of these agents in a range of cancers.